Bayer will provide CAD $1.5 million (USD$1 million) toward two studies to evaluate its chloroquine and interferon beta-1b combination therapies.
Bayer announced on April 21, 2020 that its Canadian branch is collaborating with the Population Health Research Institute (PHRI) to launch a clinical research program focused on identifying potential treatments against COVID-19.
Bayer will provide CAD $1.5 million (USD$1 million) toward two studies to evaluate its chloroquine and interferon beta-1b combination therapies, a Bayer press release said. PHRI will enroll 6000 participants into the studies from more than 60 research sites across Ontario and internationally.
“Specifically, an outpatient study will evaluate the combination of chloroquine with azithromycin to see if this treatment can prevent deterioration leading to hospital admission, while a second study will evaluate the combination of chloroquine with azithromycin, as well as interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19,” said Salim Yusuf, executive director of PHRI, in the press release. “Our goal is to assess the value of these and other therapies rapidly so that the results can inform practice as soon as possible.”
“Treatments against COVID-19 are urgently needed as no validated options are currently available,” added Dr. Mike Devoy, member of the Executive Committee of Bayer AG's Pharmaceuticals Division and chief medical officer, in the press release. “We want to contribute to the global fight against the coronavirus through our products and expertise and look forward to partnering with the PHRI.”
Source: Bayer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.